Teva's 2013 Forecast Is Below Wall Street Estimates

Teva Pharmaceutical Industries, the world's biggest maker of generic drugs, forecast profit and revenue for calendar 2013 that fell short of analysts' estimates.

The Israel-based company, which posted a higher-than-expected quarterly profit earlier this month on strong U.S. revenue, forecast an adjusted profit of $4.85 to $5.15 per share in 2013 on revenue of $19.5 billion to $20.5 billion.

Analysts' average forecast is $5.71 per share on revenue of $20.85 billion, according to Thomson Reuters I/B/E/S.

Teva expects revenue from its generic drugs of $10.3 billion to $10.7 billion next year, and sales of branded medications of $7.6 billion to $8 billion.

The company expects sales of its drug Copaxone, for multiple sclerosis, to range between $3.7 billion and $3.9 billion.